- Home
- ALEC vs OCCI Comparison
ALEC vs OCCI Comparison
Compare ALEC & OCCI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALEC
- OCCI
- Stock Information
- Founded
- ALEC 2013
- OCCI N/A
- Country
- ALEC United States
- OCCI United States
- Employees
- ALEC N/A
- OCCI N/A
- Industry
- ALEC Biotechnology: Biological Products (No Diagnostic Substances)
- OCCI Trusts Except Educational Religious and Charitable
- Sector
- ALEC Health Care
- OCCI Finance
- Exchange
- ALEC Nasdaq
- OCCI Nasdaq
- Market Cap
- ALEC 162.6M
- OCCI 146.8M
- IPO Year
- ALEC 2019
- OCCI N/A
- Fundamental
- Price
- ALEC $1.18
- OCCI $6.47
- Analyst Decision
- ALEC Buy
- OCCI
- Analyst Count
- ALEC 7
- OCCI 0
- Target Price
- ALEC $4.10
- OCCI N/A
- AVG Volume (30 Days)
- ALEC 528.1K
- OCCI 115.8K
- Earning Date
- ALEC 05-07-2025
- OCCI 12-11-2023
- Dividend Yield
- ALEC N/A
- OCCI 24.32%
- EPS Growth
- ALEC N/A
- OCCI N/A
- EPS
- ALEC N/A
- OCCI N/A
- Revenue
- ALEC $100,558,000.00
- OCCI N/A
- Revenue This Year
- ALEC N/A
- OCCI N/A
- Revenue Next Year
- ALEC $40.79
- OCCI $10.19
- P/E Ratio
- ALEC N/A
- OCCI N/A
- Revenue Growth
- ALEC 3.60
- OCCI N/A
- 52 Week Low
- ALEC $1.13
- OCCI $5.47
- 52 Week High
- ALEC $6.78
- OCCI $10.15
- Technical
- Relative Strength Index (RSI)
- ALEC 35.06
- OCCI 40.79
- Support Level
- ALEC $1.26
- OCCI $5.92
- Resistance Level
- ALEC $1.36
- OCCI $7.17
- Average True Range (ATR)
- ALEC 0.08
- OCCI 0.23
- MACD
- ALEC -0.00
- OCCI -0.03
- Stochastic Oscillator
- ALEC 18.92
- OCCI 44.00
About ALEC Alector Inc.
Alector Inc is a clinical-stage biopharmaceutical company. It is engaged in developing a novel therapeutic approach for the treatment of neurodegeneration. The firm is involved in developing therapies that are designed to simultaneously counteract pathologies by restoring healthy immune function to the brain. Its pipeline products include AL001, AL002, AL003, and AL101.
About OCCI OFS Credit Company Inc.
OFS Credit Co Inc is a non-diversified, closed-end management investment company. Its investment objective is to generate current income, with a secondary objective to generate capital appreciation. The company invests in floating rate credit instruments and other structured credit investments, including; collateralized loan obligation (CLO) debt and subordinated (i.e., residual or equity) securities; traditional corporate credit investments, including leveraged loans and high yield bonds; opportunistic credit investments, including stressed and distressed credit situations and long/short credit investments; and other credit-related instruments.